Log In
Print
BCIQ
Print
Print this Print this
 

CMV gB/MF59

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionVaccine consisting of recombinant human cytomegalovirus (CMV) glycoprotein B with MF59 adjuvant
Molecular Target Human cytomegalovirus (CMV) glycoprotein B
Mechanism of ActionVaccine
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationCytomegalovirus (CMV)
Indication DetailsPrevent cytomegalovirus (CMV)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today